Benchmark Reiterates Speculative Buy Rating for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ:FBIO – Get Rating)‘s stock had its “speculative buy” rating reaffirmed by research analysts at Benchmark in a note issued to investors on Thursday, Benzinga reports. They presently have a $5.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on FBIO. Roth Capital reaffirmed a […]

Related Keywords

,Fortress Biotech Inc ,Wells Fargo Company ,Morgan Stanley ,Biotechnology Product Development ,Advisor Group Holdings Inc ,Charles Schwab Investment Management Inc ,Cantor Fitzgerald ,Connor Clark Lunn Investment Management Ltd ,Fortress Biotech ,Get Rating ,Group Holdings ,Schwab Investment Management ,Lunn Investment Management ,Wells Fargo ,Dermatology Product Sales ,Fortress Biotech Daily ,Nasdaq Fbio ,Fbio ,Medical ,21976u10 ,Reiterated Rating ,Benchmark Co ,